SIGA Technologies Inc. · NASDAQ:SIGA
SIGA Technologies — Investor Presentation (September 2024)
27 slides from SIGA Technologies's investor presentation, September 2024
Slide 1: Company Overview
Company Overview A Leader in Global Health & Infectious Diseases 1
Slide 2: Forward Looking Statements
Forward Looking Statements 2
Slide 3: Contents
Contents 1 Introduction 2 Era of Emerging Viruses 3 TPOXX® 4 Growth Strategy 5 Financial Summary
Slide 4: SIGA at a Glance
SIGA at a Glance Stellar Revenue Generation TPOXX Strong Expertise 25+ Countries >$1bn of Procurement Contracts A Foundational Franchise & Infectious Disease, Public Where Products from 10+ years Working with Trusted Treatment for Health, and Government Are Sold Governments Smallpox & Mpox (2) Contr
Slide 5: SIGA is a Leader in Global Health and Infectious Disease
SIGA is a Leader in Global Health and Infectious Disease Fully Integrated Infectious Disease Capabilities Foundation for Continued Attractive Growth Highly profitable, commercial stage pharmaceutical company Near term opportunities for TPOXX indication expansions (mpox in operating within infectious
Slide 6: Executing on our Strategy for Growth
Executing on our Strategy for Growth KEY COMPETITIVE STRATEGIC TRENDS ADVANTAGE PRIORITIES Greater awareness on the need for Government Contracting & Continue our partnership Resulting in: preparedness in the event of an Relations with the U.S. Government outbreak Strong Financial Supply & Distribut
Slide 7: Comprehensive Capabilities Provide Strong Foundation
Comprehensive Capabilities Provide Strong Foundation Proven R&D capabilities Close coordination with government agencies to jointly Development develop high-impact therapies Deep Government Expertise Ongoing label expansions Contracting for TPOXX Experience Entrenched relationships with key governme
Slide 8: Experienced Leadership in Infectious Diseases and Government Relations
Experienced Leadership in Infectious Diseases and Government Relations Diem Nguyen, PhD, MBA Dan Luckshire Dennis Hruby Chief Executive Officer Chief Financial Officer Chief Scientific Officer Visionary: Spearheaded $11 bn revenue Operational Excellence and Financial World Renowned Infectious Diseas
Slide 9: Persistent, Durable Financial Performance Over Time
Persistent, Durable Financial Performance Over Time Revenues ($mm) Pre-tax Operating Income ($mm) $140 $85 $89 $84 $125 $134 $111 $43 2020 2021 2022 2023 2020 2021 2022 2023 Capital Management(1) ($mm) Averages for 2020 – 2023 ($mm) $46 $43 $128 $29 $26 $75 2020 2021 2022 2023 REVENUES PRE-TAX OPERA
Slide 10: Era of Emerging Viruses
Era of Emerging Viruses 10
Slide 11: Emergence of New Viruses Threaten Health Security
Emergence of New Viruses Threaten Health Security 2022 Orthopox MPOX 2020 An orthopoxvirus Corona causing mortality in up 2014-2018 COVID-19 to 10% of cases Filovirus depending on clade A disease that causes 2016 EBOLA respiratory illness with symptoms such as a Flavivirus A virus that causes cough,
Slide 12: Orthopox Threatens Global Health through Natural Occurrence or Potential Bioweapon Warfare
Orthopox Threatens Global Health through Natural Occurrence or Potential Bioweapon Warfare 12
Slide 13: Smallpox Remains a Significant Threat Today
Smallpox Remains a Significant Threat Today Highly contagious and fatal disease in susceptible population 2018 2022 2023 2024 2024 U.S. FDA approves Mpox outbreak spreads from Clade 1 mpox outbreak in U.S. Bipartisan Commission on Biodefense WHO declares mpox a public TPOXX Nigeria to Europe & ROW,
Slide 14: Global Outbreak Demonstrated the Need for Orthopox Antiviral Therapies
Global Outbreak Demonstrated the Need for Orthopox Antiviral Therapies to Help Mitigate Ongoing Threats 2022 Mpox Rapid Containment Ongoing Outbreak Response Threat Mpox belongs to orthopox family TPOXX quickly identified as a CDC and WHO concerned mpox(1) is a forewarning potentially effective trea
Slide 15: TPOXX: A Differentiated Product
TPOXX: A Differentiated Product 15
Slide 16: Orthopox Family Encompasses a Spectrum of Diverse Diseases
Orthopox Family Encompasses a Spectrum of Diverse Diseases Orthopoxvirus infections can cause arange of febrile rash illnesses in humans, from fairly benign, localized skin infections to severe systemic infections. There are four orthopoxvirus species known to cause human disease: VARIOLA VIRUS (SMA
Slide 17: TPOXX is a Clinically Differentiated Medical Countermeasure
TPOXX is a Clinically Differentiated Medical Countermeasure antivirals vaccines TPOXX TEMBEXA® ACAM2000® IMVANEX/IMVAMUNE/ Tecovirimat SIGA (CMX001/brincidofovir) (plus other replicating JYNNEOS® (MVA-BN®) (ST-246/tecovirimat) vaccinia vaccine) ▪ First FDA-approved drug with ▪ FDA-approved drug with
Slide 18: Demonstrated Track-Record of >$1B Successful Long-Standing Government Contracts for TPOXX
Demonstrated Track-Record of >$1B Successful Long- Standing Government Contracts for TPOXX 2011 TPOXX CONTRACT 2018 TPOXX CONTRACT PROCUREMENT DURATION 2011-2018 2018-current KEY AGENCY INVOLVED U.S. Biomedical Advanced Research U.S. Biomedical Advanced Research and Dev. Authority (“BARDA”) and Dev.
Slide 19: Growth Strategy
Growth Strategy 19
Slide 20: Advancing TPOXX Regulatory Approvals to Accelerate Growth into New Formulations and Indications
Advancing TPOXX Regulatory Approvals to Accelerate Growth into New Formulations and Indications TPOXX Franchise is the Foundation for Expansion with over $1bn in Multi-Year Contracts PEP Program Mpox Program Pediatric Program (post-exposure prophylaxis) Addresses time gap between exposure and Critic
Slide 21: TPOXX PEP Aims to Expand Health Benefits When Exposed to Smallpox
TPOXX PEP Aims to Expand Health Benefits When Exposed to Smallpox Antiviral Post-Exposure Prophylaxis Antiviral Treatment (Developing Label Expansion) (FDA Approved) VACCINE (HEALTH SECURITY GAP) TPOXX INCUBATION (ASYMPTOMATIC STAGE) FEVER RASH DAY 1 DAY 4 DAY 14 DAY 17 DAY 20 INFECTION INFECTIOUS S
Slide 22: TPOXX (tecovirimat) Clinical Trials for Mpox
TPOXX (tecovirimat) Clinical Trials for Mpox MOSAIC Observational (treated and not PLATINUM-CAN RCT (tecovirimat PLATINUM-UK RCT (tecovirimat vs. EPOXI RCT (tecovirimat vs. placebo) – treated with tecovirimat or other vs. placebo) – McGill University: placebo) – University of Oxford: UK University M
Slide 23: TPOXX (tecovirimat) Clinical Results in Mpox
TPOXX (tecovirimat) Clinical Results in Mpox The top line data from the PALM 007 study conducted in the DRC was reported in August 2024. While tecovirimat did not reach statistical significance on its primary endpoint of being superior to placebo in lesion resolution for all patients, we believe it
Slide 24: Cultivate Partnerships to Expand Global Access
Cultivate Partnerships to Expand Global Access Collaborating with Governments and Other Partners on Heath Security is Best-in-Class Core Competency ▪ Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Strong Long-Standing ▪ Biomedical Advanced Research and Development Authority (BAR
Slide 25: Financial Summary
Financial Summary 25
Slide 26: Strong Financial Performance
Strong Financial Performance 1 2 3 U.S. Government Orders under International Orders Financial Results Current Contracts ▪ ~$400 mm of TPOXX (1.2 mm courses) ▪ Over $100 mm of international oral TPOXX ▪ Cumulative pre-tax operating income of ordered for SNS over the past 4 years ordered by more than
Slide 27: Key Takeaways
Key Takeaways Leveraging Infectious Expanding Successful Driving Organic Expanding Platform Delivering Robust Disease Foundation TPOXX Franchise Growth Initiatives with Inorganic Growth Financial Performance Leading health security and Proven track record of Multiple organic growth Attractive opport
SIGA Technologies — Investor Presentation (September 2024) on 6ix